NovaBridge Biosciences (NBP) Accumulated Expenses (2021 - 2026)

NovaBridge Biosciences (NBP) has reported Accumulated Expenses for 5 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses rose 5.71% year-over-year to $2.8 million; the TTM figure through Dec 2025 stood at $2.8 million (up 5.71% YoY), while the FY2025 annual figure was $2.8 million, up 5.71% from the prior year.
• Accumulated Expenses improved to $2.8 million in Q4 2025 per NBP's latest filing, from $1.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $8.2 million in Q4 2021 and bottomed at $1.3 million in Q2 2025.
• Historically, Accumulated Expenses has averaged $4.2 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses grew 10.41% — and 2024, when it slumped 61.07%.
• NovaBridge Biosciences' Accumulated Expenses stood at $8.2 million in 2021, then fell by 25.58% to $6.1 million in 2022, then rose by 10.41% to $6.8 million in 2023, then plunged by 61.07% to $2.6 million in 2024, then advanced by 5.71% to $2.8 million in 2025.
• Business Quant data shows NBP's Accumulated Expenses at $2.8 million in Q4 2025, $1.8 million in Q3 2025, and $1.3 million in Q2 2025.